IgA Nephropathy Disease Treatment Market - Strategic Insights and Forecasts (2026-2031)

The IgA Nephropathy Disease Treatment market is forecast to grow at a CAGR of 13.6%, reaching USD 676.8 million in 2031 from USD 357.6 million in 2026.

The need for IgA nephropathy disease treatment is estimated to grow over the coming years on account of the increasing prevalence of kidney diseases. Research is being conducted to develop new and effective treatment methods and continue to offer growth opportunities for the market players during the forecast period.

Moreover, clearances and approval of new drugs as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups will have a positive impact on the market growth. For instance, the US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.

Additionally, in May 2022, Calliditas launched its educational program on IgA Nephropathy called “IgAN Connect” which will provide necessary tools and sources to people who have either recently been diagnosed with IgA Nephropathy or are living for many years. Such drug approval and clearances coupled with education programs relating to IgA Nephropathy present a positive outlook for the IgA Nephropathy market over the coming years

IgA Nephropathy Disease Treatment Market Growth Drivers:

• The growing prevalence of chronic kidney disease is driving the market growth globally. 

The incidences of chronic kidney diseases are increasing the demand for IgA nephropathy which is boosting the market growth. The development of new pathogenic mechanisms and a strong pipeline of innovative prospective therapeutics are anticipated to both play a significant role in the growth of the IgA Nephropathy market. 

In addition, sedentary lifestyles, excessive smoking, increased alcohol consumption, and an increase in obesity all contribute to the disease's rising occurrence. For instance, as per the report of Centers for Disease Control and Prevention, published in 2023, the people suffering from CKD in the United States with an age range between 18 to 44 was 6.30% of the overall population of that age range, for people aged between 45-64 was 12.30% and that for 65+ people it was 33.70%, hence the IgA nephropathy disease treatment market is anticipated to experience considerable expansion throughout the projected period.

IGA Nephropathy Disease Treatment Market Restraints:

• High R&D costs associated with developing effective IGAN treatment can act as an obstacle to market growth 

IgA nephropathy though is a rare disease but is progressive in nature and the varied test requirements to understand the root cause and how to treat it are complex in nature thereby posing a challenge to physicians and medical examiners. Moreover, the ongoing clinical trials to provide a better therapeutic strategy for treating such disease also require high capital costs associated with research and testing which further poses an obstacle to the market expansion

IGA Nephropathy Disease Treatment Market Segment Analysis:

• Urine tests, based on tests will account for a considerable market share.  

By test, urine test is anticipated to hold a significant market share as when a patient presents with symptoms that may suggest IgA nephropathy, a urine test is one of the initial diagnostic tools used by healthcare professionals. The urinalysis helps detect the presence of red blood cells, white blood cells, and protein in the urine, all of which can be indicative of kidney damage and inflammation associated with IgA nephropathy. The urine tests are also imperative in evaluating the effectiveness of treatment strategies.

Hence, the prevalence of IgA nephropathy has been increasing globally, leading to a larger patient population in need of diagnostic and monitoring services. As awareness about the disease grows, more individuals are seeking medical attention, resulting in a higher demand for urine tests for accurate diagnosis and disease management. Moreover, the healthcare industry has also been witnessing significant advancements in urine testing technologies. Modern urinalysis methods can provide more accurate and sensitive results, enabling healthcare professionals to detect even subtle changes in kidney function and the presence of abnormal substances in the urine.

IgA Nephropathy Disease Treatment Market Geographical Outlook:

• North America will continue to hold a remarkable share of the market during the forecast period.

Geographically, the IGA nephropathy disease treatment market has been segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. 

During the forecast period, the North American region is expected to grow at a constant rate and will constitute a considerable market share fueled by the growing chronic disease prevalence in major regional economies. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. 

According to the Centers for Disease Control and Prevention, nearly 14% of the country’s total population or 35.5 million Americans suffer from chronic kidney disease. Moreover, the same source also specified that by gender, women are more prone to be affected by chronic kidney disease as compared to men.

Recent developments in the IgA Nephropathy Disease Treatment Market:

• In October 2024: Otsuka Pharmaceutical, Co. Ltd. announced the results of its Phase-3 clinical trials for its anti-APRIL monoclonal antibody “Sibeprenlimab” which is used for treating adults suffering from progressive immunoglobulin A nephropathy. The positive results have provided a new scope for developing therapeutic strategies for people suffering from such progressive kidney disease. 

• In August 2024: Novartis received approval from the U.S Food and Drug Administration for its “Fabhalta® (iptacopan)” which is a first-in-class competitive inhibitor for reducing proteinuria in adults suffering from IgAN with rapid disease progression. The product aims to bolster the treatment for IgA nephropathy and address the challenges for patients. 

IgA Nephropathy Disease Treatment Market Scope: